Site Search



Carol Kruse, Ph.D.

Work Email Address:
ckruse@mednet.ucla.edu

Mailing Address:
Gonda 1554A
BOX 956901
MC 176122
Los Angeles, CA 90095
UNITED STATES

Fax Number:
310-206-2093
Work Phone Number:
310?267?2535



Login to the Faculty Database

Department / Division Affiliations
Member, Brain Research Institute, JCCC Tumor Immunology Program Area
Adjunct Professor, Neurosurgery

Research Interest:

Our laboratory manufactures the immunotherapeutic CTL and conducts the correlative laboratory and immune response experiments following treatment

The Kruse laboratory conducts both clinical and preclinical research. For our clinical studies we are participating with neurosurgeon, Dr. Linda Liau, in a Phase I dose escalation trial with intratumoral alloreactive CTL for recurrent gliomas. Our laboratory manufactures the immunotherapeutic CTL and conducts the correlative laboratory and immune response experiments following treatment. For our translational/basic studies we use glioma cell culture as a model system, in addition to syngeneic mouse and rat or human xenograft brain tumor models. In one project we are evaluating CTL generation when dendritic cells at various activation states are induced using pathogen associated molecular pattern (PAMP) molecules, such as C-type lectin receptor (CLR) or Toll-like receptor (TLR) agonists that are contained within nanoparticles. The CTL antitumor functions are assessed with tumor cells and stem cells. Another study is focused on combining innovative cellular and gene therapy approaches. We are engineering alloreactive CTL to deliver replication competent retroviruses within the brain to reach the infiltrating tumor cells. The retroviral vectors code for suicide genes such that when prodrug is administered, the transduced tumor cells will die. We are exploring this multi-modal therapy not only for primary malignant brain tumors, but for tumors metastatic to brain. A basic research project involves the development of algorithms that allow selection of allodonors to obtain robust alloreactive cytotoxic T lymphocytes (CTL) following one-way mixed lymphocyte reactions (MLR) based upon analysis of molecular HLA mismatch of responder:stimulator pairs.